In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest ®: results of a French multicentre study
Minimum inhibitory concentrations (MICs) of the antifungal agent voriconazole were determined using the Etest ® and compared with those of amphotericin B, itraconazole and fluconazole using 1986 clinical isolates of Candida spp. Voriconazole MICs were also compared with those of amphotericin B and i...
Gespeichert in:
| Veröffentlicht in: | International journal of antimicrobial agents 2005-04, Vol.25 (4), p.321-328 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 328 |
|---|---|
| container_issue | 4 |
| container_start_page | 321 |
| container_title | International journal of antimicrobial agents |
| container_volume | 25 |
| creator | Mallié, M. Bastide, J.M. Blancard, A. Bonnin, A. Bretagne, S. Cambon, M. Chandenier, J. Chauveau, V. Couprie, B. Datry, A. Feuilhade, M. Grillot, R. Guiguen, C. Lavarde, V. Letscher, V. Linas, M.D. Michel, A. Morin, O. Paugam, A. Piens, M.A. Raberin, H. Tissot, E. Toubas, D. Wade, A. |
| description | Minimum inhibitory concentrations (MICs) of the antifungal agent voriconazole were determined using the Etest
® and compared with those of amphotericin B, itraconazole and fluconazole using 1986 clinical isolates of
Candida spp. Voriconazole MICs were also compared with those of amphotericin B and itraconazole using 391 clinical isolates of
Aspergillus spp. Voriconazole was found to have more potent activity and lower MIC values than amphotericin B, itraconazole and fluconazole against
C. albicans,
C. tropicalis,
C. parapsilosis and
C. kefyr. Against
C. glabrata and
C. krusei, voriconazole was more active than either of the other two azole antifungals but had similar activity to amphotericin B. For species of
Aspergillus, MIC values of voriconazole were lower than those of amphotericin B and itraconazole against
A. fumigatus and
A. flavus, and were similar to those of amphotericin B against
A. niger. Against
A. terreus, MIC values for voriconazole and itraconazole were similar.
A. terreus is known to be resistant to amphotericin B, and this was reflected in higher MIC values compared with those of voriconazole and itraconazole. Voriconazole therefore compares very favourably with other antifungal agents against a large number of clinical isolates of
Candida and
Aspergillus spp. |
| doi_str_mv | 10.1016/j.ijantimicag.2004.11.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_02683080v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0924857905000051</els_id><sourcerecordid>67540179</sourcerecordid><originalsourceid>FETCH-LOGICAL-c505t-ca6987c3760b26b7b63393a988dce91968d279a8b841a9a52df138e1e892094e3</originalsourceid><addsrcrecordid>eNqNkc2O0zAUhSMEYsrAKyCzAIlFg50fx2ZXVTPMSJXYwNq6cW5aV24cbKdSeRtegIfgyXBoNTNLVlc6-u65PyfL3jGaM8r4p31u9jBEczAatnlBaZUzllNGn2ULJppi2UhWPs8WVBbVUtSNvMpehbCnlNVlVb_MrljdiKpkxSL7dT-Qo4nekTAFjWM0rbEmnkjEEM2wJa4naxg60wFJhazCiH5rrJ0CCeOYk-jI0Xmj3QA_ncV_kIs79GTesJ-GLVgCWxxiIFOYHW9ma_Ln92fiMUw26WkGkFuPg96RQ1KMTrhHEuLUnV5nL3qwAd9c6nX2_fbm2_puufn65X692ix1Teu41MClaHTZcNoWvG1aXpayBClEp1EyyUVXNBJEKyoGEuqi61kpkKGQBZUVltfZx7PvDqwavTmAPykHRt2tNmrWaMFFSQU9ssR-OLOjdz-mdI46mPQ9a2FANwXFm7qirJEJlGdQexeCx_7BmVE1Z6n26kmWas5SMaZSlqn37WXI1B6we-y8hJeA9xcAggbbexi0CY8c55zyel5ifeYwve9o0KugTXo2dsajjqpz5j_W-QvFXsWz</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67540179</pqid></control><display><type>article</type><title>In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest ®: results of a French multicentre study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Mallié, M. ; Bastide, J.M. ; Blancard, A. ; Bonnin, A. ; Bretagne, S. ; Cambon, M. ; Chandenier, J. ; Chauveau, V. ; Couprie, B. ; Datry, A. ; Feuilhade, M. ; Grillot, R. ; Guiguen, C. ; Lavarde, V. ; Letscher, V. ; Linas, M.D. ; Michel, A. ; Morin, O. ; Paugam, A. ; Piens, M.A. ; Raberin, H. ; Tissot, E. ; Toubas, D. ; Wade, A.</creator><creatorcontrib>Mallié, M. ; Bastide, J.M. ; Blancard, A. ; Bonnin, A. ; Bretagne, S. ; Cambon, M. ; Chandenier, J. ; Chauveau, V. ; Couprie, B. ; Datry, A. ; Feuilhade, M. ; Grillot, R. ; Guiguen, C. ; Lavarde, V. ; Letscher, V. ; Linas, M.D. ; Michel, A. ; Morin, O. ; Paugam, A. ; Piens, M.A. ; Raberin, H. ; Tissot, E. ; Toubas, D. ; Wade, A.</creatorcontrib><description>Minimum inhibitory concentrations (MICs) of the antifungal agent voriconazole were determined using the Etest
® and compared with those of amphotericin B, itraconazole and fluconazole using 1986 clinical isolates of
Candida spp. Voriconazole MICs were also compared with those of amphotericin B and itraconazole using 391 clinical isolates of
Aspergillus spp. Voriconazole was found to have more potent activity and lower MIC values than amphotericin B, itraconazole and fluconazole against
C. albicans,
C. tropicalis,
C. parapsilosis and
C. kefyr. Against
C. glabrata and
C. krusei, voriconazole was more active than either of the other two azole antifungals but had similar activity to amphotericin B. For species of
Aspergillus, MIC values of voriconazole were lower than those of amphotericin B and itraconazole against
A. fumigatus and
A. flavus, and were similar to those of amphotericin B against
A. niger. Against
A. terreus, MIC values for voriconazole and itraconazole were similar.
A. terreus is known to be resistant to amphotericin B, and this was reflected in higher MIC values compared with those of voriconazole and itraconazole. Voriconazole therefore compares very favourably with other antifungal agents against a large number of clinical isolates of
Candida and
Aspergillus spp.</description><identifier>ISSN: 0924-8579</identifier><identifier>EISSN: 1872-7913</identifier><identifier>DOI: 10.1016/j.ijantimicag.2004.11.010</identifier><identifier>PMID: 15784312</identifier><language>eng</language><publisher>London: Elsevier B.V</publisher><subject>Amphotericin B ; Amphotericin B - pharmacology ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antifungal Agents - pharmacology ; Aspergillus ; Aspergillus - classification ; Aspergillus - drug effects ; Biological and medical sciences ; Candida ; Candida - classification ; Candida - drug effects ; Drug Resistance, Fungal ; Etest ; Humans ; Itraconazole ; Itraconazole - pharmacology ; Life Sciences ; Medical sciences ; Microbial Sensitivity Tests - methods ; Microbial Sensitivity Tests - statistics & numerical data ; Pharmacology. Drug treatments ; Pyrimidines - pharmacology ; Triazoles - pharmacology ; Voriconazole</subject><ispartof>International journal of antimicrobial agents, 2005-04, Vol.25 (4), p.321-328</ispartof><rights>2005 Elsevier B.V. and the International Society of Chemotherapy</rights><rights>2005 INIST-CNRS</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c505t-ca6987c3760b26b7b63393a988dce91968d279a8b841a9a52df138e1e892094e3</citedby><cites>FETCH-LOGICAL-c505t-ca6987c3760b26b7b63393a988dce91968d279a8b841a9a52df138e1e892094e3</cites><orcidid>0000-0001-6870-3800</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0924857905000051$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16660659$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15784312$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.inrae.fr/hal-02683080$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Mallié, M.</creatorcontrib><creatorcontrib>Bastide, J.M.</creatorcontrib><creatorcontrib>Blancard, A.</creatorcontrib><creatorcontrib>Bonnin, A.</creatorcontrib><creatorcontrib>Bretagne, S.</creatorcontrib><creatorcontrib>Cambon, M.</creatorcontrib><creatorcontrib>Chandenier, J.</creatorcontrib><creatorcontrib>Chauveau, V.</creatorcontrib><creatorcontrib>Couprie, B.</creatorcontrib><creatorcontrib>Datry, A.</creatorcontrib><creatorcontrib>Feuilhade, M.</creatorcontrib><creatorcontrib>Grillot, R.</creatorcontrib><creatorcontrib>Guiguen, C.</creatorcontrib><creatorcontrib>Lavarde, V.</creatorcontrib><creatorcontrib>Letscher, V.</creatorcontrib><creatorcontrib>Linas, M.D.</creatorcontrib><creatorcontrib>Michel, A.</creatorcontrib><creatorcontrib>Morin, O.</creatorcontrib><creatorcontrib>Paugam, A.</creatorcontrib><creatorcontrib>Piens, M.A.</creatorcontrib><creatorcontrib>Raberin, H.</creatorcontrib><creatorcontrib>Tissot, E.</creatorcontrib><creatorcontrib>Toubas, D.</creatorcontrib><creatorcontrib>Wade, A.</creatorcontrib><title>In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest ®: results of a French multicentre study</title><title>International journal of antimicrobial agents</title><addtitle>Int J Antimicrob Agents</addtitle><description>Minimum inhibitory concentrations (MICs) of the antifungal agent voriconazole were determined using the Etest
® and compared with those of amphotericin B, itraconazole and fluconazole using 1986 clinical isolates of
Candida spp. Voriconazole MICs were also compared with those of amphotericin B and itraconazole using 391 clinical isolates of
Aspergillus spp. Voriconazole was found to have more potent activity and lower MIC values than amphotericin B, itraconazole and fluconazole against
C. albicans,
C. tropicalis,
C. parapsilosis and
C. kefyr. Against
C. glabrata and
C. krusei, voriconazole was more active than either of the other two azole antifungals but had similar activity to amphotericin B. For species of
Aspergillus, MIC values of voriconazole were lower than those of amphotericin B and itraconazole against
A. fumigatus and
A. flavus, and were similar to those of amphotericin B against
A. niger. Against
A. terreus, MIC values for voriconazole and itraconazole were similar.
A. terreus is known to be resistant to amphotericin B, and this was reflected in higher MIC values compared with those of voriconazole and itraconazole. Voriconazole therefore compares very favourably with other antifungal agents against a large number of clinical isolates of
Candida and
Aspergillus spp.</description><subject>Amphotericin B</subject><subject>Amphotericin B - pharmacology</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antifungal Agents - pharmacology</subject><subject>Aspergillus</subject><subject>Aspergillus - classification</subject><subject>Aspergillus - drug effects</subject><subject>Biological and medical sciences</subject><subject>Candida</subject><subject>Candida - classification</subject><subject>Candida - drug effects</subject><subject>Drug Resistance, Fungal</subject><subject>Etest</subject><subject>Humans</subject><subject>Itraconazole</subject><subject>Itraconazole - pharmacology</subject><subject>Life Sciences</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests - methods</subject><subject>Microbial Sensitivity Tests - statistics & numerical data</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyrimidines - pharmacology</subject><subject>Triazoles - pharmacology</subject><subject>Voriconazole</subject><issn>0924-8579</issn><issn>1872-7913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc2O0zAUhSMEYsrAKyCzAIlFg50fx2ZXVTPMSJXYwNq6cW5aV24cbKdSeRtegIfgyXBoNTNLVlc6-u65PyfL3jGaM8r4p31u9jBEczAatnlBaZUzllNGn2ULJppi2UhWPs8WVBbVUtSNvMpehbCnlNVlVb_MrljdiKpkxSL7dT-Qo4nekTAFjWM0rbEmnkjEEM2wJa4naxg60wFJhazCiH5rrJ0CCeOYk-jI0Xmj3QA_ncV_kIs79GTesJ-GLVgCWxxiIFOYHW9ma_Ln92fiMUw26WkGkFuPg96RQ1KMTrhHEuLUnV5nL3qwAd9c6nX2_fbm2_puufn65X692ix1Teu41MClaHTZcNoWvG1aXpayBClEp1EyyUVXNBJEKyoGEuqi61kpkKGQBZUVltfZx7PvDqwavTmAPykHRt2tNmrWaMFFSQU9ssR-OLOjdz-mdI46mPQ9a2FANwXFm7qirJEJlGdQexeCx_7BmVE1Z6n26kmWas5SMaZSlqn37WXI1B6we-y8hJeA9xcAggbbexi0CY8c55zyel5ifeYwve9o0KugTXo2dsajjqpz5j_W-QvFXsWz</recordid><startdate>20050401</startdate><enddate>20050401</enddate><creator>Mallié, M.</creator><creator>Bastide, J.M.</creator><creator>Blancard, A.</creator><creator>Bonnin, A.</creator><creator>Bretagne, S.</creator><creator>Cambon, M.</creator><creator>Chandenier, J.</creator><creator>Chauveau, V.</creator><creator>Couprie, B.</creator><creator>Datry, A.</creator><creator>Feuilhade, M.</creator><creator>Grillot, R.</creator><creator>Guiguen, C.</creator><creator>Lavarde, V.</creator><creator>Letscher, V.</creator><creator>Linas, M.D.</creator><creator>Michel, A.</creator><creator>Morin, O.</creator><creator>Paugam, A.</creator><creator>Piens, M.A.</creator><creator>Raberin, H.</creator><creator>Tissot, E.</creator><creator>Toubas, D.</creator><creator>Wade, A.</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0001-6870-3800</orcidid></search><sort><creationdate>20050401</creationdate><title>In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest ®: results of a French multicentre study</title><author>Mallié, M. ; Bastide, J.M. ; Blancard, A. ; Bonnin, A. ; Bretagne, S. ; Cambon, M. ; Chandenier, J. ; Chauveau, V. ; Couprie, B. ; Datry, A. ; Feuilhade, M. ; Grillot, R. ; Guiguen, C. ; Lavarde, V. ; Letscher, V. ; Linas, M.D. ; Michel, A. ; Morin, O. ; Paugam, A. ; Piens, M.A. ; Raberin, H. ; Tissot, E. ; Toubas, D. ; Wade, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c505t-ca6987c3760b26b7b63393a988dce91968d279a8b841a9a52df138e1e892094e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Amphotericin B</topic><topic>Amphotericin B - pharmacology</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antifungal Agents - pharmacology</topic><topic>Aspergillus</topic><topic>Aspergillus - classification</topic><topic>Aspergillus - drug effects</topic><topic>Biological and medical sciences</topic><topic>Candida</topic><topic>Candida - classification</topic><topic>Candida - drug effects</topic><topic>Drug Resistance, Fungal</topic><topic>Etest</topic><topic>Humans</topic><topic>Itraconazole</topic><topic>Itraconazole - pharmacology</topic><topic>Life Sciences</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests - methods</topic><topic>Microbial Sensitivity Tests - statistics & numerical data</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyrimidines - pharmacology</topic><topic>Triazoles - pharmacology</topic><topic>Voriconazole</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mallié, M.</creatorcontrib><creatorcontrib>Bastide, J.M.</creatorcontrib><creatorcontrib>Blancard, A.</creatorcontrib><creatorcontrib>Bonnin, A.</creatorcontrib><creatorcontrib>Bretagne, S.</creatorcontrib><creatorcontrib>Cambon, M.</creatorcontrib><creatorcontrib>Chandenier, J.</creatorcontrib><creatorcontrib>Chauveau, V.</creatorcontrib><creatorcontrib>Couprie, B.</creatorcontrib><creatorcontrib>Datry, A.</creatorcontrib><creatorcontrib>Feuilhade, M.</creatorcontrib><creatorcontrib>Grillot, R.</creatorcontrib><creatorcontrib>Guiguen, C.</creatorcontrib><creatorcontrib>Lavarde, V.</creatorcontrib><creatorcontrib>Letscher, V.</creatorcontrib><creatorcontrib>Linas, M.D.</creatorcontrib><creatorcontrib>Michel, A.</creatorcontrib><creatorcontrib>Morin, O.</creatorcontrib><creatorcontrib>Paugam, A.</creatorcontrib><creatorcontrib>Piens, M.A.</creatorcontrib><creatorcontrib>Raberin, H.</creatorcontrib><creatorcontrib>Tissot, E.</creatorcontrib><creatorcontrib>Toubas, D.</creatorcontrib><creatorcontrib>Wade, A.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>International journal of antimicrobial agents</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mallié, M.</au><au>Bastide, J.M.</au><au>Blancard, A.</au><au>Bonnin, A.</au><au>Bretagne, S.</au><au>Cambon, M.</au><au>Chandenier, J.</au><au>Chauveau, V.</au><au>Couprie, B.</au><au>Datry, A.</au><au>Feuilhade, M.</au><au>Grillot, R.</au><au>Guiguen, C.</au><au>Lavarde, V.</au><au>Letscher, V.</au><au>Linas, M.D.</au><au>Michel, A.</au><au>Morin, O.</au><au>Paugam, A.</au><au>Piens, M.A.</au><au>Raberin, H.</au><au>Tissot, E.</au><au>Toubas, D.</au><au>Wade, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest ®: results of a French multicentre study</atitle><jtitle>International journal of antimicrobial agents</jtitle><addtitle>Int J Antimicrob Agents</addtitle><date>2005-04-01</date><risdate>2005</risdate><volume>25</volume><issue>4</issue><spage>321</spage><epage>328</epage><pages>321-328</pages><issn>0924-8579</issn><eissn>1872-7913</eissn><abstract>Minimum inhibitory concentrations (MICs) of the antifungal agent voriconazole were determined using the Etest
® and compared with those of amphotericin B, itraconazole and fluconazole using 1986 clinical isolates of
Candida spp. Voriconazole MICs were also compared with those of amphotericin B and itraconazole using 391 clinical isolates of
Aspergillus spp. Voriconazole was found to have more potent activity and lower MIC values than amphotericin B, itraconazole and fluconazole against
C. albicans,
C. tropicalis,
C. parapsilosis and
C. kefyr. Against
C. glabrata and
C. krusei, voriconazole was more active than either of the other two azole antifungals but had similar activity to amphotericin B. For species of
Aspergillus, MIC values of voriconazole were lower than those of amphotericin B and itraconazole against
A. fumigatus and
A. flavus, and were similar to those of amphotericin B against
A. niger. Against
A. terreus, MIC values for voriconazole and itraconazole were similar.
A. terreus is known to be resistant to amphotericin B, and this was reflected in higher MIC values compared with those of voriconazole and itraconazole. Voriconazole therefore compares very favourably with other antifungal agents against a large number of clinical isolates of
Candida and
Aspergillus spp.</abstract><cop>London</cop><cop>Amsterdam</cop><cop>New York, NY</cop><pub>Elsevier B.V</pub><pmid>15784312</pmid><doi>10.1016/j.ijantimicag.2004.11.010</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-6870-3800</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0924-8579 |
| ispartof | International journal of antimicrobial agents, 2005-04, Vol.25 (4), p.321-328 |
| issn | 0924-8579 1872-7913 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_02683080v1 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Amphotericin B Amphotericin B - pharmacology Antibiotics. Antiinfectious agents. Antiparasitic agents Antifungal Agents - pharmacology Aspergillus Aspergillus - classification Aspergillus - drug effects Biological and medical sciences Candida Candida - classification Candida - drug effects Drug Resistance, Fungal Etest Humans Itraconazole Itraconazole - pharmacology Life Sciences Medical sciences Microbial Sensitivity Tests - methods Microbial Sensitivity Tests - statistics & numerical data Pharmacology. Drug treatments Pyrimidines - pharmacology Triazoles - pharmacology Voriconazole |
| title | In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest ®: results of a French multicentre study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T21%3A02%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20susceptibility%20testing%20of%20Candida%20and%20Aspergillus%20spp.%20to%20voriconazole%20and%20other%20antifungal%20agents%20using%20Etest%20%C2%AE:%20results%20of%20a%20French%20multicentre%20study&rft.jtitle=International%20journal%20of%20antimicrobial%20agents&rft.au=Malli%C3%A9,%20M.&rft.date=2005-04-01&rft.volume=25&rft.issue=4&rft.spage=321&rft.epage=328&rft.pages=321-328&rft.issn=0924-8579&rft.eissn=1872-7913&rft_id=info:doi/10.1016/j.ijantimicag.2004.11.010&rft_dat=%3Cproquest_hal_p%3E67540179%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67540179&rft_id=info:pmid/15784312&rft_els_id=S0924857905000051&rfr_iscdi=true |